- Home
- BIOA vs EVMN Comparison
BIOA vs EVMN Comparison
Compare BIOA & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIOA | EVMN |
|---|---|---|
| Founded | 2015 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 241.3M |
| IPO Year | 2024 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BIOA | EVMN |
|---|---|---|
| Price | $5.47 | $5.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $32.56 | $22.33 |
| AVG Volume (30 Days) | ★ 830.4K | 808.3K |
| Earning Date | 11-05-2026 | 11-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 66.21 | ★ 75.23 |
| EPS | ★ N/A | N/A |
| Revenue | $8,995,000.00 | ★ $13,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $97.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 85.71 |
| 52 Week Low | $4.81 | $5.09 |
| 52 Week High | $25.96 | $33.20 |
Technical Indicators
Market Signals| Indicator | BIOA | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 20.22 |
| Support Level | N/A | N/A |
| Resistance Level | $8.53 | $13.35 |
| Average True Range (ATR) | 0.37 | 0.39 |
| MACD | 0.10 | 0.06 |
| Stochastic Oscillator | 35.92 | 3.53 |
Price Performance
Historical ComparisonAbout BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.